Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)

BACKGROUND: S-1, an oral fluoropyrimidine, plus cisplatin (SP) is a standard regimen for advanced gastric cancer (AGC) in East Asia. To date, no studies have evaluated the efficacy and safety of trastuzumab combined with SP in patients with human epidermal growth factor receptor type 2 (HER2)-positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurokawa, Y, Sugimoto, N, Miwa, H, Tsuda, M, Nishina, S, Okuda, H, Imamura, H, Gamoh, M, Sakai, D, Shimokawa, T, Komatsu, Y, Doki, Y, Tsujinaka, T, Furukawa, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950868/
https://www.ncbi.nlm.nih.gov/pubmed/24473399
http://dx.doi.org/10.1038/bjc.2014.18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950868/
https://www.ncbi.nlm.nih.gov/pubmed/24473399
http://dx.doi.org/10.1038/bjc.2014.18

Ejemplares similares